Pharmaceuticals, Biotechnology and Life Sciences
HERCULES, Calif.–(BUSINESS WIRE)–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products,…
WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral…
Eli lilly is encouraged by the results of the COAST-X trial, which support its belief that Taltz could become the first IL-17A antagonist to be approved in the U.S. for people with non-radiographic axSpA, said Christi Shaw, president, Lilly Bio-Medicines.
Pfizer and Eli lilly have announced top-line results from a Phase 3 study evaluating tanezumab 2.5mg and 5 mg.
Veracyte has named Alfred “Freddie” Bowie, Jr., Ph.D., as vicepresident, corporate and business development.
Teva has launched generic version of VESIcare (solifenacin succinate) Tablets, 5 mg and 10 mg, in the U.S.
Winther trial shows RNA profiling togetherwith DNA testing matches more patients with advanced cancer topersonalized therapies than DNA profiling for tumor mutations alone.
Rising Pharma Holdings has completed the purchase of the assets of RisingPharmaceuticals and Rising’s subsidiaries on a cash-free and debt-freebasis.
Preclinical studies indicatethat targeting both E-selectin and CXCR4 with a single compound couldimprove efficacy in the treatment of cancers that involve the bonemarrow such as AML and multiple myeloma or in solid tumors thatmetastasize to the bone, such as prostate cancer and breast cancer.
Novus said the results from single-dose phase 1 studies met theprimary objectives and demonstrated a favorable safety and tolerabilityprofile